# A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

> **NCT00753415** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 37 (actual)

## Conditions studied

- Non-Small Cell Lung Carcinoma
- Breast Cancer
- Melanoma
- Upper GI Tract Carcinoma
- Colon Carcinoma
- Renal Cell Carcinoma
- Bladder Carcinoma
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** V935
- **BIOLOGICAL:** V934-EP

## Key facts

- **NCT ID:** NCT00753415
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753415, "A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00753415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*